Growth Hormone Deficiency (GHD) is a rare endocrine disorder characterized by insufficient production of growth hormone by the pituitary gland. This deficiency leads to impaired growth in children and can cause metabolic issues, reduced muscle mass, and decreased bone density in adults. Early diagnosis and hormone replacement therapy are essential to improve growth outcomes and overall health.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Cases of Growth Hormone Deficiency
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases of Growth Hormone Deficiency
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases of Pediatric Growth Hormone Deficiency
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases of Adult Growth Hormone Deficiency
</li>
<li dir="ltr" aria-level="1">
Gender-specific Cases of Growth Hormone Deficiency
</li>
<li dir="ltr" aria-level="1">
Etiology-specific Cases of Growth Hormone Deficiency
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-epidemiology-forecast">Growth Hormone Deficiency Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Growth Hormone Deficiency prevalence in the 7MM was around 206K in 2023.
</li>
<li dir="ltr" aria-level="1">
Diagnosed cases totaled approximately 165K in 2023.
</li>
<li dir="ltr" aria-level="1">
Prevalence is expected to grow at a CAGR of 0.4% through 2034.
</li>
<li dir="ltr" aria-level="1">
In 2023, the US accounted for 51% of diagnosed pediatric cases.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK accounted for 36% of diagnosed cases.
</li>
<li dir="ltr" aria-level="1">
Japan accounted for 13% of diagnosed cases.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market">Growth Hormone Deficiency Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The 7MM Growth Hormone Deficiency market was valued at about USD 1,380.5 million in 2023 and is expected to grow through 2025&ndash;2034.
</li>
<li dir="ltr" aria-level="1">
The US market accounted for approximately USD 873 million in 2023, with growth driven by new therapy launches.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK markets totaled around USD 370 million in 2023, representing 27% of the 7MM market.
</li>
</ul>
<h3 dir="ltr">Growth Hormone Deficiency Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Increasing diagnosis rates due to improved awareness and screening.
</li>
<li dir="ltr" aria-level="1">
Launch of novel and more effective growth hormone therapies.
</li>
<li dir="ltr" aria-level="1">
Rising pediatric and adult patient populations require hormone replacement.
</li>
</ul>
<h3 dir="ltr">Growth Hormone Deficiency Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
The high cost of growth hormone therapies is limiting patient access.
</li>
<li dir="ltr" aria-level="1">
Strict regulatory requirements are delaying drug approvals.
</li>
<li dir="ltr" aria-level="1">
Limited awareness and diagnosis in certain regions restricts market growth.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-pipeline-insight">Growth Hormone Deficiency Key Therapies</a></h3>
<ul>
<li dir="ltr" aria-level="1">
LUM-201 (ibutamoren)
</li>
<li dir="ltr" aria-level="1">
SCO-240
</li>
</ul>
<h3 dir="ltr">Growth Hormone Deficiency Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Novo Nordisk
</li>
<li dir="ltr" aria-level="1">
Ascendis Pharma
</li>
<li dir="ltr" aria-level="1">
Pfizer/OPKO Health
</li>
<li dir="ltr" aria-level="1">
JCR Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Eli Lilly
</li>
<li dir="ltr" aria-level="1">
Lumos Pharma
</li>
<li dir="ltr" aria-level="1">
SCOHIA PHARMA
</li>
</ul>
And others.

Growth Hormone Deficiency Market Infographics

Growth Hormone Deficiency Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape